Table 1.
Patient sociodemographic and clinical characteristics at initial diagnosis of early-stage NSCLC †, overall and per disease stage at initial diagnosis.
| Overall (N = 319) | Stage I (N = 115) | Stage II (N = 98) | Stage III (N = 106) | ||
|---|---|---|---|---|---|
| Age (years) | median (IQR) | 69.0 (62.0–76.0) | 70.0 (62.0–76.0) | 65.5 (61.0–74.0) | 70.0 (60.0–76.0) |
| <70, % (n/N) | 51.7 (165/319) | 49.6 (57/115) | 58.2 (57/98) | 48.1 (51/106) | |
| Male, % (n/N) | 53.3 (170/319) | 44.3 (51/115) | 53.1 (52/98) | 63.2 (67/106) | |
| Ever smokers (current & former), ‡ % (n/N) | 92.8 (270/291) | 88.3 (91/103) | 95.6 (86/90) | 94.9 (93/98) | |
| Pack-years of smoking, median (IQR) | 40.0 (29.3–50.0) | 36.3 (20.5–50.0) | 40.0 (30.0–50.0) | 45.0 (30.0–52.5) | |
| BMI (kg/m2), ‡ median (IQR) | 25.1 (22.3–28.4) | 26.0 (22.5–29.7) | 25.9 (23.4–29.0) | 24.0 (21.5–26.6) | |
| ECOG performance status score 0–1, ‡ % (n/N) | 89.3 (201/225) | 92.9 (79/85) | 90.8 (59/65) | 84.0 (63/75) | |
| History of other primary malignancies, % (n/N) | 21.6 (69/319) | 25.2 (29/115) | 20.4 (20/98) | 18.9 (20/106) | |
| Histological disease diagnosis, % (n/N) | 94.4 (301/319) | 98.3 (113/115) | 91.8 (90/98) | 92.5 (98/106) | |
| Primary tumor size (cm), ‡ median (IQR) | 2.9 (1.8–4.7) | 1.9 (1.3–2.7) | 3.8 (2.4–4.8) | 4.7 (2.5–7.2) | |
| Most common primary tumor histology, ‡,⌠ % (n/N) | Non-squamous | 50.6 (159/314) | 63.2 (72/114) | 47.4 (46/97) | 39.8 (41/103) |
| Squamous | 35.4 (111/314) | 21.1 (24/114) | 38.1 (37/97) | 48.5 (50/103) | |
| Adenosquamous | 11.5 (36/314) | 11.4 (13/114) | 12.4 (12/97) | 10.7 (11/103) | |
| Imaging testing performed, % (n/N) | 97.2 (310/319) | 96.5 (111/115) | 98.0 (96/98) | 97.2 (103/106) | |
| Most common ∫ type of testing performed, % (n/N) | CT | 92.9 (288/310) | 95.5 (106/111) | 95.8 (92/96) | 87.4 (90/103) |
| PET-CT | 53.9 (167/310) | 55.9 (62/111) | 55.2 (53/96) | 50.5 (52/103) | |
| Brain MRI | 25.5 (79/310) | 24.3 (27/111) | 32.3 (31/96) | 20.4 (21/103) | |
For variables not following a normal distribution in at least one of the study subpopulations, a uniform presentation of median (IQR) was applied. † Date of confirmation of initial NSCLC diagnosis or within the preceding 30 days; ‡ Data was missing/unknown in a subset of patients for ‘smoking status’ (n = 28), ‘ECOG performance status’ (n = 94), ‘BMI’ (n = 34), ‘primary tumor size’ (n = 63), ‘primary tumor histology’ (n = 5), and ‘type of imaging testing’ (n = 9). ⌠ Six more subtypes were reported in ≤2 patients each. ∫ Reported in ≥10.0% in any of the examined subpopulations. Abbreviations: BMI, Body Mass Index; CT, Computed Tomography; ECOG, Eastern Cooperative Oncology Group; IQR, Interquartile Range; MRI, Magnetic Resonance Imaging; N, number of patients with available data; n, number of patients with variable; NSCLC, Non-Small Cell Lung Cancer; PET-CT, Positron Emission Tomography–Computed Tomography.